[{"id":"c4169409-3fac-483f-bce1-948601165775","acronym":"","url":"https://clinicaltrials.gov/study/NCT03132792","created_at":"2022-04-24T09:56:49.214Z","updated_at":"2024-07-02T16:36:04.770Z","phase":"Phase 1","brief_title":"AFPᶜ³³²T in Advanced HCC","source_id_and_acronym":"NCT03132792","lead_sponsor":"Adaptimmune","biomarkers":" AFP","pipe":" | ","alterations":" AFP expression","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ADP-A2AFP"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 05/08/2017","start_date":" 05/08/2017","primary_txt":" Primary completion: 07/07/2021","primary_completion_date":" 07/07/2021","study_txt":" Completion: 07/07/2036","study_completion_date":" 07/07/2036","last_update_posted":"2022-08-29"},{"id":"dbbe31a7-e955-4a0a-8dcd-5eb1bc91b383","acronym":"","url":"https://clinicaltrials.gov/study/NCT03888859","created_at":"2021-01-18T19:09:34.497Z","updated_at":"2024-07-02T16:36:32.648Z","phase":"Phase 1","brief_title":"ET1402L1-ARTEMIS™2 T Cells in Alpha Fetoprotein (AFP) Expressing Hepatocellular Carcinoma","source_id_and_acronym":"NCT03888859","lead_sponsor":"First Affiliated Hospital Xi'an Jiaotong University","biomarkers":" HLA-A • IFNG • IL6 • TNFA • AFP • IL2 • IL10 • IL4","pipe":" | ","alterations":" HLA-A*02 • AFP expression","tags":["HLA-A • IFNG • IL6 • TNFA • AFP • IL2 • IL10 • IL4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • AFP expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ET1402L1-ARTEMIS T cells"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 12/06/2017","start_date":" 12/06/2017","primary_txt":" Primary completion: 04/13/2019","primary_completion_date":" 04/13/2019","study_txt":" Completion: 12/08/2020","study_completion_date":" 12/08/2020","last_update_posted":"2021-03-29"},{"id":"eba3f2d8-df2f-4db2-8b50-7d1ebd4b5a6b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04368182","created_at":"2021-06-30T14:53:52.902Z","updated_at":"2024-07-02T16:36:45.519Z","phase":"Phase 1","brief_title":"AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma","source_id_and_acronym":"NCT04368182","lead_sponsor":"Zhejiang University","biomarkers":" HLA-A • AFP","pipe":" | ","alterations":" HLA-A*02 • AFP expression","tags":["HLA-A • AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • AFP expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e C-TCR055"],"overall_status":"Unknown status","enrollment":" Enrollment 3","initiation":"Initiation: 04/13/2020","start_date":" 04/13/2020","primary_txt":" Primary completion: 08/31/2020","primary_completion_date":" 08/31/2020","study_txt":" Completion: 11/30/2021","study_completion_date":" 11/30/2021","last_update_posted":"2020-04-29"},{"id":"182788c6-1780-477a-87bc-0e5bf73a6189","acronym":"","url":"https://clinicaltrials.gov/study/NCT03971747","created_at":"2021-06-30T14:53:40.918Z","updated_at":"2024-07-02T16:36:46.431Z","phase":"Phase 1","brief_title":"AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma","source_id_and_acronym":"NCT03971747","lead_sponsor":"Cellular Biomedicine Group Ltd.","biomarkers":" HLA-A • AFP","pipe":" | ","alterations":" HLA-A*02 • AFP expression","tags":["HLA-A • AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • AFP expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e C-TCR055"],"overall_status":"Unknown status","enrollment":" Enrollment 9","initiation":"Initiation: 08/06/2019","start_date":" 08/06/2019","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 04/01/2021","study_completion_date":" 04/01/2021","last_update_posted":"2020-04-07"},{"id":"3e9f16ba-7ef3-4a62-bda2-2d123d6d52a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03965546","created_at":"2021-01-18T19:30:34.813Z","updated_at":"2024-07-02T16:36:57.170Z","phase":"Phase 1","brief_title":"ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Liver Cancer","source_id_and_acronym":"NCT03965546","lead_sponsor":"First Affiliated Hospital Xi'an Jiaotong University","biomarkers":" HLA-A • IFNG • IL6 • TNFA • AFP • IL2 • IL10","pipe":" | ","alterations":" HLA-A*02 • AFP expression • IL10 elevation • IL2 expression • IL6 expression","tags":["HLA-A • IFNG • IL6 • TNFA • AFP • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • AFP expression • IL10 elevation • IL2 expression • IL6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • ET1402L1-ARTEMIS T cells"],"overall_status":"Unknown status","enrollment":" Enrollment 27","initiation":"Initiation: 05/30/2019","start_date":" 05/30/2019","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 06/01/2022","study_completion_date":" 06/01/2022","last_update_posted":"2019-08-08"}]